Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action for Herbal Medicines in Stroke Treatment and Prevention

Annually, tens of millions of first-ever strokes occur in the world; however, currently there is lack of effective and widely applicable pharmacological treatments for stroke patients. Herbal medicines, characterized as multi-constituent, multi-target and multi-effect, have been acknowledged with conspicuous effects in treating stroke, and attract extensive interest of researchers although the mechanism of action is yet unclear. In this work, we introduce an innovative systems-pharmacology method that combines pharmacokinetic prescreening, target fishing and network analysis to decipher the mechanisms of action of 10 herbal medicines like Salvia miltiorrhizae, Ginkgo biloba and Ephedrae herba which are efficient in stroke treatment and prevention. Our systematic analysis results display that, in these anti-stroke herbal medicines, 168 out of 1285 constituents with the favorable pharmacokinetic profiles might be implicated in stroke therapy, and the systematic use of these compounds probably acts through multiple mechanisms to synergistically benefit patients with stroke, which can roughly be classified as preventing ischemic inflammatory response, scavenging free radicals and inhibiting neuronal apoptosis against ischemic cerebral damage, as well as exhibiting lipid-lowering, anti-diabetic, anti-thrombotic and antiplatelet effects to decrease recurrent strokes. Relying on systems biology-based analysis, we speculate that herbal medicines, being characterized as the classical combination therapies, might be not only engaged in multiple mechanisms of action to synergistically improve the stroke outcomes, but also might be participated in reducing the risk factors for recurrent strokes.

[1]  M. Bermejo,et al.  In Silico Prediction of Caco‐2 Cell Permeability by a Classification QSAR Approach , 2011, Molecular informatics.

[2]  Johannes Novak,et al.  Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. , 2008, Journal of agricultural and food chemistry.

[3]  Yang Ling,et al.  Prediction of human intestinal absorption based on molecular indices , 2007 .

[4]  Yonghua Wang,et al.  Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication , 2012, Integrative biology : quantitative biosciences from nano to macro.

[5]  Jinan Wang,et al.  Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. , 2013, Journal of ethnopharmacology.

[6]  Tao Yang,et al.  Glycoprotein IIb/IIIa Antagonist, Murine 7E3 F(ab′)2, and Tissue Plasminogen Activator in Focal Ischemia: Evaluation of Efficacy and Risk of Hemorrhage with Combination Therapy , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  E. Wouters,et al.  Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. , 2007, The Journal of nutrition.

[8]  Igor V. Tetko,et al.  Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices , 2001, J. Chem. Inf. Comput. Sci..

[9]  Wenhua Zheng,et al.  Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway , 2009, Experimental Brain Research.

[10]  S. L. Mehta,et al.  Molecular targets in cerebral ischemia for developing novel therapeutics , 2007, Brain Research Reviews.

[11]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[12]  I. Tetko,et al.  Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. , 2004, Journal of pharmaceutical sciences.

[13]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[14]  B. Meldrum Cytoprotective therapies in stroke. , 1995, Current opinion in neurology.

[15]  Lin-lin Yin,et al.  Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. , 2006, European journal of pharmacology.

[16]  Xiao-ling Fang,et al.  Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs , 2009, Archives of pharmacal research.

[17]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[18]  Jing-Shan Shi,et al.  Pharmacological actions of Uncaria alkaloids, rhynchophylline and isorhynchophylline. , 2003, Acta pharmacologica Sinica.

[19]  Hua Yu,et al.  A Novel Chemometric Method for the Prediction of Human Oral Bioavailability , 2012, International journal of molecular sciences.

[20]  E. Kılıç,et al.  The phosphatidylinositol‐3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Tingjun Hou,et al.  Development of Reliable Aqueous Solubility Models and Their Application in Druglike Analysis , 2007, J. Chem. Inf. Model..

[22]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[23]  Dong Hyun Kim,et al.  Oroxylin A, a Flavonoid, Stimulates Adult Neurogenesis in the Hippocampal Dentate Gyrus Region of Mice , 2010, Neurochemical Research.

[24]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[25]  N. Sucher,et al.  Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. , 1999, Trends in pharmacological sciences.

[26]  Hee-Jung Choi,et al.  Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. , 2006, Biochemical pharmacology.

[27]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[28]  Shiwen Zhou,et al.  Antihypertensive and neuroprotective activities of rhynchophylline: the role of rhynchophylline in neurotransmission and ion channel activity. , 2010, Journal of ethnopharmacology.

[29]  Jiyin Zhou,et al.  Isorhynchophylline: A plant alkaloid with therapeutic potential for cardiovascular and central nervous system diseases. , 2012, Fitoterapia.

[30]  M. Kim,et al.  Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model , 2013, Laboratory animal research.

[31]  Zhang Shu-wei Prediction of BBB permeation based on molecular indices , 2007 .

[32]  C. Hsieh,et al.  Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction , 2010, Chinese medicine.

[33]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[34]  M. Di Napoli,et al.  Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke , 2003, Stroke.

[35]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[36]  Chao Huang,et al.  Systems pharmacology in drug discovery and therapeutic insight for herbal medicines , 2014, Briefings Bioinform..

[37]  Xue Xu,et al.  A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment , 2012, PloS one.

[38]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[39]  J. Ha,et al.  Antidiabetes and Antiobesity Effect of Cryptotanshinone via Activation of AMP-Activated Protein Kinase , 2007, Molecular Pharmacology.

[40]  F. Liao,et al.  Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. , 2004, Clinical hemorheology and microcirculation.

[41]  G. Donnan,et al.  Blood Pressure–Lowering for Secondary Prevention of Stroke: ACE Inhibition Is the Key Controversies in Stroke , 2003 .

[42]  B. Cheng,et al.  The flavonoid baicalin protects against cerebrovascular dysfunction and brain inflammation in experimental heatstroke , 2007, Neuropharmacology.

[43]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[44]  M. Kawai,et al.  Flavonoids and related compounds as anti-allergic substances. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[45]  E. Trinka,et al.  Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. , 2012, Drug discovery today.

[46]  Bo Wu,et al.  Meta-Analysis of Traditional Chinese Patent Medicine for Ischemic Stroke , 2007, Stroke.

[47]  C. Iadecola Bright and dark sides of nitric oxide in ischemic brain injury , 1997, Trends in Neurosciences.

[48]  Gun-Hee Kim,et al.  Oroxylin A increases BDNF production by activation of MAPK–CREB pathway in rat primary cortical neuronal culture , 2011, Neuroscience Research.

[49]  Shi-hong Zhang,et al.  Dan Shen agents for acute ischaemic stroke. , 2007, The Cochrane database of systematic reviews.

[50]  K. Chan,et al.  The protective effects of natural products on blood-brain barrier breakdown. , 2012, Current medicinal chemistry.

[51]  K. Pang Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[52]  Xiaojie Xu,et al.  1. Applications of genetic algorithms to the prediction of blood-brain partitioning of a large set of drugs , 2002 .

[53]  S. Planey,et al.  The influence of lipophilicity in drug discovery and design , 2012, Expert opinion on drug discovery.

[54]  Damian Szklarczyk,et al.  STITCH 3: zooming in on protein–chemical interactions , 2011, Nucleic Acids Res..

[55]  Hua Yu,et al.  A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data , 2012, PloS one.

[56]  K. Seibert,et al.  Mediation of inflammation by cyclooxygenase-2. , 1995, Agents and actions. Supplements.

[57]  Hao Ye,et al.  HIT: linking herbal active ingredients to targets , 2010, Nucleic Acids Res..

[58]  T. Herdegen,et al.  PPAR-gamma: therapeutic target for ischemic stroke. , 2007, Trends in pharmacological sciences.

[59]  V. Feigin Herbal medicine in stroke: does it have a future? , 2007, Stroke.

[60]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[61]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Sun Young Park,et al.  Neuroprotection by methanol extract of Uncaria rhynchophylla against global cerebral ischemia in rats. , 2002, Life sciences.

[63]  J. Kalbfleisch,et al.  TLR2 Ligand Induces Protection against Cerebral Ischemia/Reperfusion Injury via Activation of Phosphoinositide 3-Kinase/Akt Signaling , 2011, The Journal of Immunology.

[64]  L. Yue,et al.  Inhibitory effect of rhynchophylline on platelet aggregation and thrombosis. , 1992, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[65]  T. Herdegen,et al.  PPAR-γ: therapeutic target for ischemic stroke , 2007 .

[66]  G. Donnan,et al.  Evaluation of Combination Therapy in Animal Models of Cerebral Ischemia , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[67]  G. Du,et al.  Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats. , 2000, Acta pharmacologica Sinica.

[68]  P. Kuo Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. , 2005, Life sciences.

[69]  M. Choi,et al.  Whitening activity of luteolin related to the inhibition of cAMP pathway in α-MSH-stimulated B16 melanoma cells , 2008, Archives of pharmacal research.

[70]  C. Shi,et al.  Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice , 2010, International journal of molecular sciences.

[71]  M. Oh,et al.  Acacetin Attenuates Neuroinflammation via Regulation the Response to LPS Stimuli In Vitro and In Vivo , 2012, Neurochemical Research.

[72]  K. Lee,et al.  New developments in the chemistry and biology of the bioactive constituents of tanshen , 2007, Medicinal research reviews.

[73]  Jian-Dong Huang,et al.  Salvianolic Acid B Inhibits Hydrogen Peroxide-Induced Endothelial Cell Apoptosis through Regulating PI3K/Akt Signaling , 2007, PloS one.

[74]  Da-yuan Zhu,et al.  Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. , 2001, Life sciences.

[75]  E. Lo,et al.  Reduction of Tissue Plasminogen Activator-Induced Hemorrhage and Brain Injury by Free Radical Spin Trapping after Embolic Focal Cerebral Ischemia in Rats , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[76]  G. Hageman,et al.  Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. , 2005, Free radical biology & medicine.